Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2009. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction.
- Transaction Price: $39.58 per American Depositary Receipt (ADR).
- Transaction Type: Increase in interest following dividend re-investment.
- Dividend Date: October 8, 2009.
Material Changes
The filing reports an increase in the shareholding interest of Mr. D J Phelan to 207.34 units (likely representing ADRs or a specific plan unit count) as of October 20, 2009. This change resulted from the automatic re-investment of dividends paid to shareholders.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification of a director's transaction under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the total number of shares held by Mr. D J Phelan post-transaction to understand the magnitude of the 207.34 unit increase.
- Confirm the dividend yield and re-investment terms applicable to the GlaxoSmithKline Performance Share Plan as of October 2009.
- Check subsequent filings to determine if this transaction triggered any further disclosure thresholds.